Development of Biodegradable Microcapsules as Carrier for Oral Controlled Delivery of Amifostine

Mandal, Tarun K.; Bostanian, Levon A; Graves, Richard A; Chapman, S.R.; Womack, I.

doi:10.1081/ddc-120002849

Cited by 16 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cyt-PLGA NP had onset at 45.81°C, endset 54.04°C, and peak at 50.02°C. These endothermic curves showed that the drug peak was absent in nanoparticle formulation, indicating drug was dispersed as an amorphous state in the nanoparticle (28). Hence, it could be concluded that in the prepared PLGA NP, the drug was present in the amorphous phase and may have been homogeneously dispersed in the PLGA matrix.…”

Section: Differential Scanning Calorimetry Studiesmentioning

confidence: 93%

Modified Nanoprecipitation Method for Preparation of Cytarabine-Loaded PLGA Nanoparticles

2010

View full text Add to dashboard Cite

Abstract. The present investigation was aimed at developing cytarabine-loaded poly(lactide-coglycolide) (PLGA)-based biodegradable nanoparticles by a modified nanoprecipitation which would have sustained release of the drug. Nine batches were prepared as per 3 2 factorial design to optimize volume of the cosolvent (0.22-0.37 ml) and volume of non-solvent (1.7-3.0 ml). A second 3 2 factorial design was used for optimization of drug: polymer ratio (1:5) and stirring time (30 min) based on the two responses, mean particle size (125±2.5 nm), and percentage entrapment efficiency (21.8±2.0%) of the Cyt-PLGA nanoparticles. Optimized formulation showed a zeta potential of −29.7 mV indicating good stability; 50% w/w of sucrose in Cyt-PLGA NP was added successfully as cryoprotectant during lyophilization for freeze-dried NPs and showed good dispersibility with minimum increase in their mean particle sizes. The DSC thermograms concluded that in the prepared PLGA NP, the drug was present in the amorphous phase and may have been homogeneously dispersed in the PLGA matrix. In vitro drug release from the pure drug was complete within 2 h, but was sustained up to 24 h from PLGA nanoparticles with Fickian diffusion. Stability studies showed that the developed PLGA NPs should be stored in the freeze-dried state at 2-8°C where they would remain stable in terms of both mean particle size and drug content for 2 months.

show abstract

Section: Differential Scanning Calorimetry Studiesmentioning

confidence: 93%

Modified Nanoprecipitation Method for Preparation of Cytarabine-Loaded PLGA Nanoparticles

2010

View full text Add to dashboard Cite

show abstract

“…in pharmacy for drug delivery [5]. Several techniques have been developed • to produce microparticulate release systems for water-soluble drugs, • including the solvent evaporation method [6][7][8][9][10][11][12], interfacial reaction techniques [13][14][15][16], and suspension/dispersion methods [17][18][19]. Here, we report on the successful encapsulation of ZA into polystyrene via the solvent evaporation method and on the characterization of these microcapsules.…”

Section: Introductionmentioning

confidence: 99%

Encapsulated Zosteric Acid Embedded in Poly[3-hydroxyalkanoate] Coatings?Protection against Biofouling

et al. 2004

View full text Add to dashboard Cite

The natural, non-toxic antifouling compound zosteric acid (ZA, p-coumaric acid sulfate) was encapsulated in polystyrene (PS) microcapsules (30 mg ZAil g PS) with an efficiency of 30 % via an in-liquid drying process. Electron micrographs showed microcapsules with smooth surfaces and a mean diameter of 200 µm. The FIB method was used to cross-section a microcapsule in order to visualize the inner capsule structure and to localize ZA via element analysis. Coatings of a biocompatible polyester, poly[3-hydroxyalkanoate-co-3-hydroxyalkenoate] (PHAE), were prepared on microscopic slides. These coatings contained dispersed ZA (PHAE/ZA) or ZAloaded PS microcapsules (PHAE/PS(ZA)). The release of ZA was monitored vi'a conductivy measurements in water and was 4 µgcm-2 d-1 for PHAE/ZA and 0.9 µgcm-2 d-1 for PHAE/PS(ZA) coatings. To follow the initial steps ofbiofilm formation, coated slides were exposed to activated sludge arid analyzed for cell adhesion with ESEM. ZA was effective during the burst release time of the PHAE/ZA coating, but no significant differences in biofouling were observed after 48 h. This was attributed to the minimal effective release rate of ZA, which is approximately IO µgcm• 2 d-1 •

show abstract

“…PLGA Amifostine A solvent evaporation technique was used for Amifostine encapsulation and oral controlled release. It was observed that 50% of the drug was released within the first 6 h and 92% within 12 h. [118] Plasmid DNA (pDNA) pDNA vaccine encapsulated PLGA microcapsules was synthesized via a solvent evaporation method. The pDNA was protected from degradation in the GI system.…”

Section: Methodsmentioning

confidence: 99%

Micro and nanoscale technologies in oral drug delivery

Ahadian

Finbloom

Mofidfar

et al. 2020

Advanced Drug Delivery Reviews

169

View full text Add to dashboard Cite

Micro and nanocarriers Micro and nanoscale technologies Oral drug delivery Tissue models Oral administration is a pillar of the pharmaceutical industry and yet it remains challenging to administer hydrophilic therapeutics by the oral route. Smart and controlled oral drug delivery could bypass the physiological barriers that limit the oral delivery of these therapeutics. Micro-and nanoscale technologies, with an unprecedented ability to create, control, and measure micro-or nanoenvironments, have found tremendous applications in biology and medicine. In particular, significant advances have been made in using these technologies for oral drug delivery. In this review, we briefly describe biological barriers to oral drug delivery and micro and nanoscale fabrication technologies. Micro and nanoscale drug carriers fabricated using these technologies, including bioadhesives, microparticles, micropatches, and nanoparticles, are described. Other applications of micro and nanoscale technologies are discussed, including fabrication of devices and tissue engineering models to precisely control or assess oral drug delivery in vivo and in vitro, respectively. Strategies to advance translation of micro and nanotechnologies into clinical trials for oral drug delivery are mentioned. Finally, challenges and future prospects on further integration of micro and nanoscale technologies with oral drug delivery systems are highlighted.

show abstract

Development of Biodegradable Microcapsules as Carrier for Oral Controlled Delivery of Amifostine

Cited by 16 publications

References 10 publications

Modified Nanoprecipitation Method for Preparation of Cytarabine-Loaded PLGA Nanoparticles

Modified Nanoprecipitation Method for Preparation of Cytarabine-Loaded PLGA Nanoparticles

Encapsulated Zosteric Acid Embedded in Poly[3-hydroxyalkanoate] Coatings?Protection against Biofouling

Micro and nanoscale technologies in oral drug delivery

Contact Info

Product

Resources

About